Stoke Therapeutics Inc. (STOK): Price and Financial Metrics
STOK Price/Volume Stats
| Current price | $3.94 | 52-week high | $16.48 |
| Prev. close | $3.78 | 52-week low | $3.63 |
| Day low | $3.75 | Volume | 211,900 |
| Day high | $3.98 | Avg. volume | 331,703 |
| 50-day MA | $5.58 | Dividend yield | N/A |
| 200-day MA | $8.72 | Market Cap | 174.37M |
STOK Stock Price Chart Interactive Chart >
STOK POWR Grades
- Value is the dimension where STOK ranks best; there it ranks ahead of 56.01% of US stocks.
- The strongest trend for STOK is in Growth, which has been heading down over the past 177 days.
- STOK ranks lowest in Sentiment; there it ranks in the 4th percentile.
STOK Stock Summary
- STOKE THERAPEUTICS INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than only 11.65% of US listed stocks.
- The ratio of debt to operating expenses for STOKE THERAPEUTICS INC is higher than it is for about just 0.33% of US stocks.
- STOK's price/sales ratio is 20.92; that's higher than the P/S ratio of 94.62% of US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to STOKE THERAPEUTICS INC are KRON, CLNN, JANX, MRTX, and ITOS.
- Visit STOK's SEC page to see the company's official filings. To visit the company's web site, go to www.stoketherapeutics.com.
STOK Valuation Summary
- In comparison to the median Healthcare stock, STOK's EV/EBIT ratio is 99.14% lower, now standing at 0.1.
- STOK's price/sales ratio has moved NA NA over the prior 52 months.
Below are key valuation metrics over time for STOK.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| STOK | 2023-09-22 | 20.9 | 1.0 | -1.8 | 0.1 |
| STOK | 2023-09-21 | 20.8 | 1.0 | -1.8 | 0.1 |
| STOK | 2023-09-20 | 22.2 | 1.0 | -1.9 | 0.0 |
| STOK | 2023-09-19 | 23.8 | 1.1 | -2.0 | -0.2 |
| STOK | 2023-09-18 | 23.7 | 1.1 | -2.0 | -0.1 |
| STOK | 2023-09-15 | 24.9 | 1.2 | -2.1 | -0.2 |
STOK's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- STOK has a Quality Grade of D, ranking ahead of 7.46% of graded US stocks.
- STOK's asset turnover comes in at 0 -- ranking 440th of 680 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows STOK's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0 | NA | -2.894 |
| 2021-03-31 | 0 | NA | -29.463 |
| 2020-12-31 | 0 | NA | -31.246 |
| 2020-09-30 | 0 | NA | -19.782 |
| 2020-06-30 | 0 | NA | -19.444 |
| 2020-03-31 | 0 | NA | -28.985 |
STOK Price Target
For more insight on analysts targets of STOK, see our STOK price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $62.88 | Average Broker Recommendation | 1.45 (Moderate Buy) |
Stoke Therapeutics Inc. (STOK) Company Bio
Stoke Therapeutics, Inc. was founded in 2014 by Professor Adrian Krainer, PhD. and Isabel Aznarez, PhD to research and develop treatments for the underlying cause of genetic diseases. The company focuses on developing antisense oligonucleotide medicines that increase gene expression to treat genetic epilepsies and other severe monogenic diseases, including genetic conditions affecting the central nervous system, eye, liver, and kidney. Stoke’s proprietary platform, Targeted Augmentation of Nuclear Gene Output (TANGO) allows for the delivery of disease-modifying therapies in a precise and controlled manner. Edward M. Kaye, M.D., currently serves as the company’s director and Chief Executive Officer.
Latest STOK News From Around the Web
Below are the latest news stories about STOKE THERAPEUTICS INC that investors may wish to consider to help them evaluate STOK as an investment opportunity.
Stoke Therapeutics to Participate in the 2023 Cantor Global Healthcare ConferenceBEDFORD, Mass., September 21, 2023--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will participate in a panel presentation at the 2023 Cantor Global Healthcare Conference on Tuesday, September 26, 2023, at 9:55 a.m. ET. |
Stoke Therapeutics Appoints Ian Smith to its Board of DirectorsBEDFORD, Mass., September 20, 2023--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Ian Smith to its Board of Directors effective September 19. |
Stoke Therapeutics Presents Data Related to the Ongoing Clinical Development of STK-001 for the Treatment of Dravet Syndrome at the 35th International Epilepsy CongressDUBLIN, September 05, 2023--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced highlights from presentations related to the ongoing clinical development of STK-001, the first potential new medicine to treat the underlying cause of Dravet syndrome. Four posters from the Company’s work in Dravet syndrome are being presented at the International |
This Under-the-Radar Growth Stock Could Soar by 277%, According to Wall StreetIf you're looking for a hidden gem in the biotech sector, you might want to check out Stoke Therapeutics (NASDAQ: STOK). This company is developing innovative therapies for rare genetic diseases that represent a high degree of unmet medical need. What makes Stoke Therapeutics an intriguing growth play? |
Stoke Therapeutics Second Quarter 2023 Earnings: Misses ExpectationsStoke Therapeutics ( NASDAQ:STOK ) Second Quarter 2023 Results Key Financial Results Net loss: US$30.7m (loss widened... |
STOK Price Returns
| 1-mo | -29.89% |
| 3-mo | -62.94% |
| 6-mo | -52.07% |
| 1-year | -69.31% |
| 3-year | -88.24% |
| 5-year | N/A |
| YTD | -57.31% |
| 2022 | -61.53% |
| 2021 | -61.26% |
| 2020 | 118.68% |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...